Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Lu AG06466 on CYP Substrates PK
NCT04713254Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABX-1431 in fibromyalgia (FM), post-traumatic stress disorder (PTSD), multiple sclerosis (MS) and 1 more, sponsored by Lundbeck. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Zero to Infinity for Midazolam at Day 15, Area Under the Plasma Concentration-Time Curve From Zero to Infinity for Metoprolol at Day 15 and 4 more. Started Dec 2020; status: completed.
02
Drugs
ABX-1431
03
Conditions
fibromyalgia (FM)post-traumatic stress disorder (PTSD)multiple sclerosis (MS)epilepsy
Beyond the preview
Go deeper on NCT04713254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04713254.